AbbVie shares drop almost 2% after strong Q3 results and raised dividend

Traders Union
All News
Stocks
AbbVie slides 1.9% today to $289.26

Highlights

AbbVie reported third-quarter 2026 revenue of $17.4 billion and adjusted EPS of $3.82, both above consensus expectations.
The company raised its full-year 2026 revenue forecast to $67.8 billion and increased its quarterly dividend by 5.2% to $1.82 per share.
AbbVie stock trades with a bullish technical structure and an 80% probability of moving to $297.69 over the next five days.

Sustained selling pressure persists despite strong results and cash generation

AbbVie reported strong third-quarter 2026 results, with revenue of $17.4 billion and adjusted EPS of $3.82, both above consensus estimates. The company raised its full-year 2026 revenue guidance to $67.8 billion and announced a 5.2% increase in its quarterly dividend to $1.82 per share, effective from the February 2027 payment. Revenue growth was driven by its immunology and neuroscience portfolios, with further mentions of progress in its pipeline and regulatory filings. Approximately $14 billion in free cash flow was generated over nine months, and AbbVie remained on track to reduce its net leverage ratio to two times within two to three years, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that ABBV's strong fundamentals and dividend hike failed to protect the stock from a sharp selloff. He remains cautious, pointing to the market's disregard for upbeat earnings and guidance. Kharitonov sees persistent overbought technicals and a stretched RSI as warning signs. He warns that short-term risks are heightened, especially with price action still vulnerable below $293.79. "Despite positive headlines, the current disconnect between technical overextension and negative price action cannot be ignored — traders should remain alert for a reversal."

Viktoras Karapetjanc, expert at Traders Union, views AbbVie's results and upgraded outlook as a foundation for continued growth. He highlights the raised dividend and strong free cash flow as signals of management confidence. Karapetjanc expects the bullish structure to draw in further demand, with upward momentum persisting above key averages. "I believe the market offers multiple setups for long exposure, as the bullish trend remains firmly supported by fundamentals and inflows."

Jainam Mehta, market strategist, observes that ABBV's gap down after positive news may signal short-term profit taking rather than a trend change. He notes the overbought oscillators contrast with still-strong price momentum, creating tactical range-trading opportunities. Mehta believes a break above $293.79 could trigger a squeeze, while a dip to $286.14 might invite dip buying. "Contrarian entries on volatility tests could pay off, as the risk-reward now favors nimble trades near range boundaries."

Overbought signals as stock consolidates amid persistent bullish momentum

AbbVie is trading above its 20-day, 50-day, and 200-day moving averages at $281.65, $269.3, and $237.1 respectively, confirming a bullish bias across short, medium, and long-term trends. The nearest trading range remains defined by the intraday floor at $286.14 and ceiling at $293.79, with the Ichimoku Kijun at $278.52 further supporting the prevailing bullish structure. Momentum signals are mixed. The MACD and ADX forecast continued buying momentum, and the RSI sits at 73.01, showing overbought conditions. The Stochastic RSI, CCI, and BBP also highlight overbought conditions, with BBP above zero confirming that buyers dominate intraday momentum. The Awesome Oscillator aligns with the bullish trend. The stock last traded at $289.26, down $5.61 or 1.9% on the session after opening with a downside gap of 1.52%. It remains mid-range for the session, with intraday volatility at 2.67%. Current price action suggests pressure following the open, reflecting some consolidation around session mid-levels even as momentum remains positive.

Earlier, analysts noted that AbbVie's bullish technical structure remained intact following the Q3 2026 financial results announcement. The latest price action introduces a layer of near-term consolidation, and traders should watch for a decisive move beyond the $293.79 resistance or below the $286.14 support to determine the next directional trend.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.